The most recent meta-analysis of systemic adverse events following intravitreal anti-VEGF revealed higher risk of death in diabetic retinopathy patients as well as higher risk of non-ocular bleeding in the patients with age-related macular degeneration6. Here, VEGFA is linked to diabetic retinopathy.